K. Gyurászová

Repression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma.

A. Biankin, O. Sansom, L. Carlin, 2020, Cancer discovery.

Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma

D. Lewis, K. Blyth, J. L. Le Quesne, 2020, bioRxiv.

Conjunction of glutathione level, NAD(P)H/FAD redox status and hypericin content as a potential factor affecting colon cancer cell resistance to photodynamic therapy with hypericin.

P. Fedoročko, J. Mikes, K. Gyurászová, 2013, Photodiagnosis and photodynamic therapy.

YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy

P. Fedoročko, J. Mikes, R. Jendželovský, 2016, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress.

M. Drysdale, H. Esumi, O. Sansom, 2018, Cancer discovery.

Cell death in cancer therapy of lung adenocarcinoma.

B. Zhivotovsky, Anna Zagryazhskaya, K. Gyurászová, 2015, The International journal of developmental biology.

Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11

O. Surova, B. Zhivotovsky, E. Tchevkina, 2015, Oncotarget.

The pathogenesis of mesothelioma is driven by a dysregulated translatome

R. Spriggs, L. Officer, M. Sereno, 2021, Nature Communications.

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma

B. Nieswandt, A. Hedley, W. Clark, 2019, Cancers.

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma

B. Nieswandt, A. Hedley, W. Clark, 2019, Cancers.